Full text is available at the source.
Abstract
Fecal microbiota transplantation (FMT) from anti-PD-1 responders resulted in clinical benefits for 6 of 13 patients with advanced solid cancers, achieving an objective response rate of 7.7%.
- Sustained changes in gut microbiota were observed following FMT.
- Clinical benefits included 1 partial response and 5 cases of stable disease.
- An objective response rate of 7.7% and a disease control rate of 46.2% were reported.
- Increased levels of cytotoxic T cells and immune cytokines were associated with clinical responses.
- Prevotella merdae Immunoactis was isolated and shown to enhance T cell activity and suppress tumor growth in mice.
- Lactobacillus salivarius and Bacteroides plebeius may inhibit anti-tumor immune responses.
Simplified